{"id":"NCT00362232","sponsor":"Bayer","briefTitle":"Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.","officialTitle":"RECORD 4 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled, Double-blind, Randomized Study of BAY59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06","primaryCompletion":"2007-01","completion":"2008-01","firstPosted":"2006-08-09","resultsPosted":"2012-06-13","lastUpdate":"2014-11-04"},"enrollment":3148,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Venous Thromboembolism"],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","otherNames":[]},{"type":"DRUG","name":"Enoxaparin","otherNames":[]},{"type":"DRUG","name":"Placebo: tablet of Rivaroxaban","otherNames":[]},{"type":"DRUG","name":"Placebo: syringes of Enoxaparin","otherNames":[]}],"arms":[{"label":"Rivaroxaban 10 mg Once Daily (OD) ((Xarelto, BAY59-7939))","type":"EXPERIMENTAL"},{"label":"Enoxaparin 30 mg twice a day (bid)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess if 10 mg BAY59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.","primaryOutcome":{"measure":"Composite Endpoint of Total Venous Thrombo Embolism (VTE) i.e.: Any Deep Vein Thromboembolism (DVT) (Proximal and/or Distal), Non Fatal Pulmonary Embolism (PE), Death of All Causes Per Protocol Population","timeFrame":"Up to 16 days after surgery","effectByArm":[{"arm":"Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939)","deltaMin":6.71,"sd":null},{"arm":"Enoxaparin 30 mg Twice a Day (Bid)","deltaMin":9.34,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":"0.036"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":124,"countries":["United States","Bulgaria","Canada","Denmark","India","Israel","Lithuania","Mexico","Norway","Pakistan","Poland","Sri Lanka","Sweden"]},"refs":{"pmids":["19411100"],"seeAlso":["http://www.clinicaltrialsregister.eu"]},"adverseEventsSummary":{"seriousAny":{"events":106,"n":1526},"commonTop":["Pyrexia","Nausea","Constipation","Oedema peripheral","Anaemia postoperative"]}}